Short answer
Lilly (Eli) (LLY) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $24.4B (up 38.6% year over year) with net income of $6.5B.
Q3 2026 key financials · XBRL
- Revenue
- $24.4B
- +38.6% YoY · +6.2% QoQ
- Net income
- $6.5B
- +15.6% YoY · −9.1% QoQ
- EPS (diluted)
- $7.23
- +16.4% YoY · −8.8% QoQ
Source: XBRL data from the Lilly (Eli) (LLY) Q3 2026 10-Q on SEC EDGAR. USD.
Lilly (Eli) Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $24,397M, up $6,796M YoY from $17,601M, driven by volume despite lower realized prices
- Gross margin 83.9% vs 82.9% YoY, with gross margin dollars of $20,464M vs $14,593M
- Best performer: Mounjaro revenue $10,723M vs $6,515M, up 64% YoY
- Cash $4.9B vs $7.3B at December 31, 2025, with $18.2B deployed to business development
- Near-term risks: Medicare uptake uncertainty, pricing pressure, counterfeit incretins, and additional manufacturing investment needs
Risk Factors
- No material changes from the December 31, 2025 Form 10-K risk factors
- Carried-forward risks remain the company’s material disclosed exposures
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Lilly (Eli) quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.